Publications

Filters: Keyword is Antineoplastic Agents  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Antineoplastic Agents
Zhao, Yufan, Donglin Zeng, Mark A. Socinski, and Michael R. Kosorok. "Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
Song, Guochen, and Anastasia Ivanova. "Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials." J Biopharm Stat 25, no. 6 (2015): 1206-14.
McLeod, Howard L.. "Cancer pharmacogenomics: early promise, but concerted effort needed." Science 339, no. 6127 (2013): 1563-6.
Ivanova, Anastasia, Barry Paul, Olga Marchenko, Guochen Song, Neerali Patel, and Stergios J. Moschos. "Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9.
Michiels, Stefan, Richard F. Potthoff, and Stephen L. George. "Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint." Stat Med 30, no. 13 (2011): 1502-18.
Zhang, Danjie, Ming-Hui Chen, Joseph G. Ibrahim, Mark E. Boye, Ping Wang, and Wei Shen. "Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials." Stat Med 33, no. 27 (2014): 4715-33.
Krens, Stefanie D., Howard L. McLeod, and Daniel L. Hertz. "Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy." Pharmacogenomics 14, no. 5 (2013): 555-74.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Sargent, Daniel J., and Stephen L. George. "Clinical trials data collection: when less is more." J Clin Oncol 28, no. 34 (2010): 5019-21.
Neely, Megan L., Howard D. Bondell, and Jung-Ying Tzeng. "A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies." Biometrics 71, no. 2 (2015): 529-37.
Yimit, Askar, Ogun Adebali, Aziz Sancar, and Yuchao Jiang. "Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
Jensen, Brian C., and Howard L. McLeod. "Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
Harbeck, Nadia, Oleg Lipatov, Mona Frolova, Dmitry Udovitsa, Eldar Topuzov, Doina Elena Ganea-Motan, Roumen Nakov, Pritibha Singh, Anita Rudy, and Kimberly Blackwell. "Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
Caron, Whitney P., John C. Lay, Alan M. Fong, Ninh M. La-Beck, Parag Kumar, Suzanne E. Newman, Haibo Zhou, Jane H. Monaco, Daniel L. Clarke-Pearson, Wendy R. Brewster et al. "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Chen, Liddy M., Joseph G. Ibrahim, and Haitao Chu. "Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309.
Chiuzan, Cody, Jonathan Shtaynberger, Gulam A. Manji, Jimmy K. Duong, Gary K. Schwartz, Anastasia Ivanova, and Shing M. Lee. "Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
Liu, Bo, Wenbin Lu, and Jiajia Zhang. "Accelerated intensity frailty model for recurrent events data." Biometrics 70, no. 3 (2014): 579-87.
Chen, Ting-Huei, and Wei Sun. "Prediction of cancer drug sensitivity using high-dimensional omic features." Biostatistics 18, no. 1 (2017): 1-14.